Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Background: The effectiveness of apatinib and cabozantinib for the treatment of radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) has been demonstrated recently. We aimed to evaluate the cost-effectiveness of these treatments from the Chinese healthcare system perspective.Method...
Saved in:
Main Authors: | Bo Shi (Author), Wenbiao Ma (Author), Hongshuai Pan (Author), Yang Shi (Author), Huan Zhang (Author), Shenghai Xing (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
mutations and aggressive histopathologic characteristics of radioiodine-refractory papillary thyroid cancer
by: Ju Yeon Pyo, et al.
Published: (2024) -
APOPTOSIS ROLE IN FORMING RADIOIODINE RESISTANCE IN DIFFERENTIATED THYROID CANCER
by: K.A. GARIPOV, et al.
Published: (2020) -
Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis
by: Xiaoyu Ji, et al.
Published: (2022) -
Pharmacoeconomic effectiveness of lenvatinib in patients with differentiated radioiodine-resistant thyroid cancer
by: S. K. Zyryanov, et al.
Published: (2018) -
Differentiated Thyroid Cancer in Adolescents: Single Center Experience and Considerations for Surgical Management and Radioiodine Treatment
by: Costanza Chiapponi, et al.
Published: (2023)